Mr Aidan Noon

Urologist in Sheffield

MB ChB (Hons) MD FRCS Ed (Urol)

GMC: 4696159

47 Valoraciones de pacientes Valorar al doctor

Call

Book online

Telemedicine

Call

Book online

Telemedicine

Mr Aidan Noon areas of expertise:

Professional statement

Mr Aidan Noon is a highly experienced consultant urological surgeon based in Sheffield, where he currently sees patients at Claremont Hospital and BMI Thornbury Hospital. Mr Aidan Noon treats patients with prostate, bladder and testicular cancer and also tends to other common urological problems, such as high PSA, blood in the urine, urinary tract infections problems with urination and lumps in the scrotum.

As part of his regular practice, Mr Noon offers surgery for patients with suspected prostate and bladder cancer, referred to Sheffield from the surrounding south Yorkshire and North Derbyshire areas. He is expert at interpreting high PSA levels and deciding on whether further investigation is necessary (prostate biopsy).
He performs surgery for patients with prostate cancer - robotic prostatectomy (RALP) and also manages patients on active surveillance or watchful waiting programs. He performs surgery for bladder cancer (TURBT) and bladder removal (radical cystectomy). He also manages patients with non-muscle-invasive bladder cancer.

Mr Aidan Noon qualified from Manchester University Medical School (awarded honours in 2000). He completed his basic surgical training in the North Western Deanery. He carried out research in the molecular biology of cancer at the University of Liverpool and was awarded a Doctor of Medicine degree (MD) in 2008.

In 2008 he started specialist training in urology in South Yorkshire (Sheffield – Royal Hallamshire Hospital). He carried out a two year Society of Urological Oncology (SUO) Fellowship at the University of Toronto, Canada (Princess Margaret Cancer Hospital, Mount Sinai Hospital and Sunnybrook Hospital). Mr Aidan Noon was trained in all aspects of urological cancer (prostate, bladder, kidney, testis and penile). He graduated from the programme in 2015 and took up a full time consultant position at Sheffield Teaching Hospital NHS Foundation Trust - Department of Urology.

Reviews

Treatments

Articles

Diplomas y publicaciones

Images

Videos

Vídeos de doctor

All about robotic assisted radical pros...

Doctor's articles

Read all articles by Mr Aidan Noon

Credentials

GMC: ‍4696159

Professional experience

• More than 20 years of experience
• Consultant Urological Surgeon, Claremont Hospital (present)
• Consultant Urological Surgeon, BMI Thornbury Hospital (present)
• Consultant Urological Surgeon,

...

Sub-specialties

• Prostate cancer
• Bladder cancer

Teaching posts

• Consultant Urological Surgeon, Sheffield Teaching Hospitals NHS Foundation Trust (2015 - present)
• Clinical Fellow, University of Toronto, Canada (2013 - 2015)
• Clinical Lecturer, University of Sheffield (2012 - 2013)

...

Education

• FRCS, Fellow of the Royal College of Surgeons (Edinburgh)
• Doctor of Medicine (MD), Molecular Biology (Renal Carcinoma), University of Liverpool (2008)
• MB ChB, University of Manchester (2000)

...

Publications and conferences

• Pang, K.H., Groves, R., Venugopal, S., Noon, A.P. and Catto, J.W., 2018. Prospective implementation of enhanced recovery after surgery protocols to radical cystectomy. European urology, 73(3), pp.363-371.
• Dobruch, J., Daneshmand, S., Fisch, M., Lotan, Y., Noon, A.P., Resnick, M.J., Shariat, S.F., Zlotta, A.R. and Boorjian, S.A., 2016. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. European urology, 69(2), pp.300-310.
• Hermanns, T., Bhindi, B., Wei, Y., Yu, J., Noon, A.P., Richard, P.O., Bhatt, J.R., Almatar, A., Jewett, M.A., Fleshner, N.E. and Zlotta, A.R., 2014. Pre-treatment neutrophil-to-lymphocyte ratio as predictor of adverse outcomes in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. British journal of cancer, 111(3), pp.444-451.
• Noon, A.P., Albertsen, P.C., Thomas, F., Rosario, D.J. and Catto, J.W.F., 2013. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. British journal of cancer, 108(7), pp.1534-1540.
• Noon, A.P., Vlatković, N., Polański, R., Maguire, M., Shawki, H., Parsons, K. and Boyd, M.T., 2010. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?. Cancer: Interdisciplinary International Journal of the American Cancer Society, 116(4), pp.780-790.

...

Professional membership

• British Medical Association
• European Association of Urology

Languages spoken

English